Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Onychomycosis/Onycholysis and Tinea Pedis Patients were required to meet all of the following in order to be eligible for entry in the study Were between 18 and 70 years of age, of any race and of either sex Were in good general health as confirmed by a medical history and brief physical examination Groups 1 and 2, presented with clinically diagnosed stable or exacerbating onychomycosis with more than 25 % involvement of one great toenail For Group 3, had mild tinea pedis (mild tinea pedis was defined as mild erythema, mild scaling, cracking or fissuring, and mild burning or pruritus) For Groups 1 and 2, had at least five toenails with onycholysis For Groups 1 and 2, a positive calcofluor (KOH) exam must have been obtained during Visit 1 from specimens taken from the affected great toenail Signed a statement of informed consent Were able to understand the requirements of the study, abide by the restrictions, and return for all of the required examinations If female, met one of the following (a) had been post-menopausal for at least one year, or (b) had a hysterectomy or tubal ligation, or (c) was using oral/systemic contraceptives or an intrauterine device at least 28 days prior to study entry and throughout the study, or (d) agreed to use spermicide in combination with barrier methods of contraception throughout the study  Any of the following excluded a patient from participating in the study Any missing toes Known hypersensitivity to terbinafine or any of the excipients in the nail lacquer Vital signs measurement that were clinically significantly outside the normal limits Liver function test values more than two times the upper limit of normal or other clinical laboratory values, which were clinically significantly outside normal limits Receipt of terbinafine tablets within 12 months or terbinafine cream or solution within six months prior to screening Participation in a clinical trial for the systemic treatment of onychomycosis within the previous two months Current treatment with rifampin, phenobarbital, phenytoin, carbamazepine, terfenadine, or digoxin Prior treatment with an investigational drug within one month prior to study start Diagnosis of psoriasis or history of psoriasis